Skip to main content
. Author manuscript; available in PMC: 2013 Nov 20.
Published in final edited form as: Gastroenterology. 2012 Nov 15;144(3):10.1053/j.gastro.2012.11.022. doi: 10.1053/j.gastro.2012.11.022

Figure 2. RYGB improves hepatic glucose homeostasis in DIO mice.

Figure 2

(A) RYGB reduced fasting glucose (left), fasting insulin (middle), and HOMA-IR (right) (n=4-11/group). (B) RYGB improved oral glucose tolerance, (C) reduced glucose-stimulated plasma insulin, and (D) improved insulin tolerance, presented as % of baseline glucose to control for differences in baseline glucose (n=5-6/group). (E) RYGB reduced basal endogenous glucose production, gluconeogenesis, and glycogenolysis as measured during week 6 using in vivo NMR metabolic flux analysis (n=5-9/group). (F) RYGB increased insulin-stimulated IRS2 tyrosine phosphorylation and protein expression (n=4/group). IP, immunoprecipitate; IB, immunoblot. *p<.05 vs. Sham, ++p<.05 vs. CRWM-Sham.